To further examine the involvement of the MET pathway with IL-32γ-induced autophagy in liver cancer cell lines, we examined the combination effects of Cabozantinib, a MET inhibiting compound, and IL-32γ overexpression on autophagy induction in liver cancer cell lines. This evidence concerns the gene MET and liver cancer.